Select Publications

Dang CT et al. Preliminary safety results of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2 overexpressed/amplified breast cancer (BCA). Proc ASCO 2008;Abstract 518.

Gnant M et al. Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12. Proc ASCO 2008;Abstract LBA4.

Norton L, Massagué J. Is cancer a disease of self-seeding? Nat Med 2006;12(8):875-8. No abstract available

Piccart-Gebhart MJ et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353(16):1659-72. Abstract

Slamon D et al. BCIRG 006: 2^nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. San Antonio Breast Cancer Symposium 2006;Abstract 52.

Smith I et al; HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 2007;369(9555):29-36. Abstract

Untch M et al; HERA Study Team. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008;19(6):1090-6. Abstract

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Home · Search

EDITOR
Neil Love, MD

INTERVIEWS

Paul E Goss, MD, PhD
- Select publications

Martine J Piccart-Gebhart, MD, PhD
- Select publications

TUMOR PANEL CASE DISCUSSION
- Select publications

INTERVIEWS (continued)

Erica L Mayer, MD, MPH
- Select publications

Maria Theodoulou, MD
- Select publications

 

Breast Cancer Update:
A CME Audio Series and Activity

Faculty Disclosures

Editor's Office